Oppenheimer & Co. Inc. increased its stake in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 25.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 65,541 shares of the company’s stock after buying an additional 13,160 shares during the period. Oppenheimer & Co. Inc. owned 0.09% of Mind Medicine (MindMed) worth $456,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Barclays PLC boosted its holdings in Mind Medicine (MindMed) by 203.6% in the third quarter. Barclays PLC now owns 136,098 shares of the company’s stock worth $775,000 after acquiring an additional 91,271 shares in the last quarter. Wellington Management Group LLP boosted its stake in Mind Medicine (MindMed) by 142.6% in the 3rd quarter. Wellington Management Group LLP now owns 185,722 shares of the company’s stock worth $1,057,000 after purchasing an additional 109,152 shares in the last quarter. Geode Capital Management LLC grew its position in Mind Medicine (MindMed) by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,677,702 shares of the company’s stock valued at $9,548,000 after purchasing an additional 162,933 shares during the last quarter. SG Americas Securities LLC increased its stake in Mind Medicine (MindMed) by 48.8% during the 4th quarter. SG Americas Securities LLC now owns 24,406 shares of the company’s stock valued at $170,000 after purchasing an additional 8,004 shares in the last quarter. Finally, State Street Corp increased its stake in Mind Medicine (MindMed) by 0.5% during the 3rd quarter. State Street Corp now owns 1,814,829 shares of the company’s stock valued at $10,326,000 after purchasing an additional 9,782 shares in the last quarter. Institutional investors own 27.91% of the company’s stock.
Mind Medicine (MindMed) Trading Up 3.3 %
Shares of NASDAQ:MNMD opened at $6.83 on Friday. Mind Medicine has a 52-week low of $5.03 and a 52-week high of $12.22. The stock has a market capitalization of $500.86 million, a price-to-earnings ratio of -3.02 and a beta of 2.57. The company has a debt-to-equity ratio of 0.09, a quick ratio of 9.00 and a current ratio of 9.00. The stock’s 50-day simple moving average is $7.42 and its two-hundred day simple moving average is $6.90.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on MNMD shares. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of Mind Medicine (MindMed) in a report on Friday. Oppenheimer reiterated an “outperform” rating and set a $20.00 target price on shares of Mind Medicine (MindMed) in a research note on Tuesday, December 17th. Evercore ISI began coverage on Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They issued an “outperform” rating and a $23.00 price target for the company. Robert W. Baird dropped their price objective on Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday. Finally, Chardan Capital assumed coverage on Mind Medicine (MindMed) in a report on Friday, December 20th. They issued a “buy” rating and a $20.00 price objective for the company. Ten investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $25.11.
Get Our Latest Report on Mind Medicine (MindMed)
Insider Transactions at Mind Medicine (MindMed)
In related news, CEO Robert Barrow sold 19,106 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $7.43, for a total value of $141,957.58. Following the completion of the sale, the chief executive officer now directly owns 526,666 shares of the company’s stock, valued at approximately $3,913,128.38. This represents a 3.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Dan Karlin sold 6,643 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $7.43, for a total transaction of $49,357.49. Following the sale, the insider now owns 338,013 shares in the company, valued at approximately $2,511,436.59. The trade was a 1.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,022 shares of company stock worth $208,203 in the last 90 days. 2.26% of the stock is currently owned by insiders.
Mind Medicine (MindMed) Profile
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Recommended Stories
- Five stocks we like better than Mind Medicine (MindMed)
- Learn Technical Analysis Skills to Master the Stock Market
- Is Myers Industries Poised for a Breakout?
- What is the Nikkei 225 index?
- Is BigBear.ai’s 25% Plunge a False Alarm or Fire Sale?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon
Want to see what other hedge funds are holding MNMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report).
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.